You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (77)

Journals (0)

1-10 of 77 results for off-label marketing

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Failure of Responsive Regulation? Pharmaceutical Marketing,Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe

Open access

Research article

First published 2021-6

Failure of Responsive Regulation? Pharmaceutical Marketing,Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe

Shai Mulinari, Courtney Davis, Piotr Ozieranski

Journal of White Collar and Corporate Crime

Select article: Investigating pharmaceutical marketing in Canada using American prosecutions

Open access

Research article

First published 2014-8

Investigating pharmaceutical marketing in Canada using American prosecutions

Rami Shoucri, Navindra Persaud

International Journal of Risk & Safety in Medicine

Select article: The CJEU’s ruling in the Novartis Farma case: Money,health and medicines

Retricted access

Research article

First published 2020-4

The CJEU’s ruling in the Novartis Farma case: Money,health and medicines

Vera Lúcia Raposo

Maastricht Journal of European and Comparative Law

Select article: Three Principles That Govern FDA Advertising and Promotion Regulation

Retricted access

Research article

First published 1997-1

Three Principles That Govern FDA Advertising and Promotion Regulation

Wayne L. Pines

Therapeutic Innovation & Regulatory Science

Select article: Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?

Open access

Review article

First published 2018

Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?

Alyssa M Peckham, Kirk E Evoy, Leslie Ochs [...]

Substance Use: Research and Treatment

Select article: Off-Label Marketing's Audiences: The 21 st Century Cures Act and the Relaxation of Standards for Evidence-Based Therapeutic and Cost-Comparative Claims

Retricted access

Research article

First published 2018-5

Off-Label Marketing's Audiences: The 21 st Century Cures Act and the Relaxation of Standards for Evidence-Based Therapeutic and Cost-Comparative Claims

Sam F. Halabi

American Journal of Law & Medicine

Select article: A Retrospective (Post-Marketing) Case Series of Patients Receiving Intramuscular (IM) Olanzapine outside of Product Doses and Indications (Off-Label): Assessing Safety and Tolerability

Open access

Research article

First published 2011

A Retrospective (Post-Marketing) Case Series of Patients Receiving Intramuscular (IM) Olanzapine outside of Product Doses and Indications (Off-Label): Assessing Safety and Tolerability

Joel W. Lamoure, Abraham Rudnick

Clinical Medicine Insights: Psychiatry

Select article: Off-Label Promotion of Prescription Medicine

Retricted access

Research article

First published 2015-5

Off-Label Promotion of Prescription Medicine

Narcyz Ghinea, Wendy Lipworth, Ian Kerridge

Therapeutic Innovation & Regulatory Science

Select article: Using Off-Label Communications to Responsibly Advance the Public Health

Retricted access

Research article

First published 2017-5

Using Off-Label Communications to Responsibly Advance the Public Health

Peter J. Pitts

Therapeutic Innovation & Regulatory Science

Select article: Off-Label Use and Prescribing What Does It Mean for the Foot and Ankle Surgeon?

Retricted access

Other

First published 2010-10

Off-Label Use and Prescribing What Does It Mean for the Foot and Ankle Surgeon?

Christopher F. Hyer

Foot & Ankle Specialist

1
2
3
•••
8
10 / page

Article type

Publication date

Subjects

Access